Economic studies in colorectal cancer: Challenges in measuring and comparing costs

Journal of the National Cancer Institute - Monographs

Volumn , Issue 46, 2013, Pages 62-78

  Yabroff, K Robin ^a   Borowski, Laurel ^a   Lipscomb, Joseph ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER REGISTRY; CANCER STAGING; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LIFE EXPECTANCY; MANAGED CARE; MEDICAL FEE; MEDICAL SERVICE; MEDICARE; PRIORITY JOURNAL; PRODUCTIVITY; CANADA; COLORECTAL NEOPLASMS; ECONOMICS; FRANCE; UNITED KINGDOM; UNITED STATES; COLORECTAL TUMOR; REVIEW;

CANADA; COLORECTAL NEOPLASMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FRANCE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 84882958463     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgt001     Document Type: Article

References (94)

1. Lipscomb J, Barnett PG, Brown ML, Lawrence W, YabroffKR. Advancing the science of health care costing. Med Care. 2009;47(7 Suppl 1):S120-S126.
2. Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47(7 Suppl 1):S82-S88.
3. Frick KD. Microcosting quantity data collection methods. Med Care. 2009;47(7 Suppl 1):S76-S81.
4. Karanikolos M, Ellis L, Coleman MP, McKee M. Health systems performance and cancer outcomes. J Natl Cancer Inst Monogr. 2013;46(1):7-12.
5. European Observatory on Health Systems and Policies. http://www.euro.who.int/en/who-we-are/partners/observatory. Accessed February 18, 2013.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
7. Howlader NA, Krapcho M, Neyman N, et al., eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. http://seer.cancer.gov/csr/1975_2008.
8. Mariotto AB, YabroffKR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.
9. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
10. Redaelli A, Cranor CW, Okano GJ, Reese PR. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics. 2003;21(17):1213-1238.
11. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25(7):537-562.
12. YabroffKR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4(11):643-656.
13. van den Hout WB, van den Brink M, Stiggelbout AM, van de Velde CJ, Kievit J. Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer. 2002;38(7):953-963.
14. Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, YabroffKR. Patterns of colorectal cancer care in the United States and Canada: a systematic review. J Natl Cancer Inst Monogr. 2013;46(1):13-35.
15. Chawla N, Butler EN, Lund J, Warren JL, Harlan LC, YabroffKR. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr. 2013;46(1):36-61.
16. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7(2):198-204.
17. Chu E, Schulman KL, McKenna EF Jr, Cartwright T. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin Colorectal Cancer. 2010;9(4):229-237.
18. Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancerattributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology. 2003;125(6): 1645-1650.
19. Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52-58.
20. Boncz I, Brodszky V, Péntek M, et al. The disease burden of colorectal cancer in Hungary. Eur J Health Econ. 2010;10(Suppl 1):S35-S40.
21. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-3530.
22. Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ. 2001;10(3):245-256.
23. Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care. 2005;43(10):1043-1048.
24. Körner H, Söreide K, Stokkeland PJ, Söreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a populationbased audit of effectiveness, costs, and compliance. J Gastrointest Surg. 2005;9(3):320-328.
25. Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer. 2006;14(11):1077-1085.
26. Lopatriello S, Amoroso D, Donati S, et al. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on firstline infusional 5-fluorouracil or oral capecitabine. Eur J Cancer. 2008;44(17):2615-2622.
27. Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet C. Economic disparities in treatment costs among ambulatory Medicaid cancer patients. J Natl Med Assoc. 2004;96(12):1565-1574.
28. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000;17(4):361-370.
29. Shugarman LR, Bird CE, Schuster CR, Lynn J. Age and gender differences in Medicare expenditures at the end of life for colorectal cancer decedents. J Womens Health (Larchmt). 2007;16(2):214-227.
30. Torres US, Almeida TE, Netinho JG. Increasing hospital admission rates and economic burden for colorectal cancer in Brazil, 1996-2008. Rev Panam Salud Publica. 2010;28(4):244-248.
31. Warren JL, YabroffKR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897.
32. Wright GE, Barlow WE, Green P, Baldwin LM, Taplin SH. Differences among the elderly in the treatment costs of colorectal cancer: how important is race? Med Care. 2007;45(5):420-430.
33. YabroffKR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640-648.
34. YabroffKR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
35. Mittmann N, Au HJ, Tu D, et al.; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101(17):1182-1192.
36. Polednak AP. Hospital charges for colorectal cancer patients first admitted through an emergency department. J Health Care Finance. 2000;27(1):44-49.
37. Maniadakis N, Pallis A, Fragoulakis V, Prezerakos P, Georgoulias V. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin. 2007;23(9):2251-2257.
38. O'Brien BD, Brown MG, Kephart G. Estimation of hospital costs for colorectal cancer care in Nova Scotia. Can J Gastroenterol. 2001;15(1):43-47.
39. Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2003;24(4):91-101.
40. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(2):440-445.
41. Howard DH, Tangka FK, SeeffLC, Richardson LC, Ekwueme DU. The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. Health Econ. 2009;18(12):1381-1393.
42. YabroffKR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009;47(7 Suppl 1):S64-S69.
43. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer. 2009;101(1):12-18.
44. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286-1291.
45. Brown ML, YabroffKR. Economic impact of cancer in the United States. In: Schottenfeld D, Faumeni JF, eds. Cancer Epidemiology and Prevention. 3rd ed. New York, NY: Oxford University Press; 2006.
46. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91-113.
47. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. 2006;94(8):1122-1129.
48. Bouvier V, Reaud JM, Gignoux M, Launoy G. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Département, France. Eur J Health Econ. 2003;4(2): 102-106.
49. Monz BU, König HH, Leidl R, Staib L, Link KH. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics. 2003;21(10):709-719.
50. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol. 2000;11(2):157-161.
51. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer. 2002;86(11):1677-1683.
52. Earle CC, Kwok A, Gazelle GS, Fuchs CS. Two schedules of second-line irinotecan for metastatic colon carcinoma. Cancer. 2004;101(11):2533-2539.
53. De Portu S, Mantovani LG, Ravaioli A, et al. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. J Chemother. 2010;22(2):125-128.
54. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303(16):1625-1631.
55. Luo Z, Bradley CJ, Dahman BA, Gardiner JC. Colon cancer treatment costs for Medicare and dually eligible beneficiaries. Health Care Financ Rev. 2010;31(1):35-50.
56. YabroffKR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer. 2009;115(18 Suppl):4362-4373.
57. Ferro SA, Myer BS, WolffDA, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008;14(11):717-725.
58. Koroukian SM, Beaird H, Madigan E, Diaz M. End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer. Health Care Financ Rev. 2006;28(2):65-80.
59. Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010;170(6):537-542.
60. Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist. 2010;15(8):883-893.
61. Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19(13):3219-3225.
62. Borie F, Daurès JP, Millat B, Trétarre B. Cost and effectiveness of followup examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg. 2004;8(5):552-558.
63. Ray GT, Collin F, Lieu T, et al. The cost of health conditions in a health maintenance organization. Med Care Res Rev. 2000;57(1):92-109.
64. YabroffKR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99(1):14-23.
65. Hisashige A, Yoshida S, Kodaira S. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer. 2008;99(8):1232-1238.
66. Lejeune C, Binquet C, Bonnetain F, et al. Estimating the cost related to surveillance of colorectal cancer in a French population. Eur J Health Econ. 2009;10(4):409-419.
67. Clerc L, Jooste V, Lejeune C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ. 2008;9(4):361-367.
68. Macafee DA, West J, Scholefield JH, Whynes DK. Hospital costs of colorectal cancer care. Clin Med Oncol. 2009;3:27-37.
69. Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T. Cost of colorectal cancer in France in 1999 [in French]. Gastroenterol Clin Biol. 2003;27(1):22-27.
70. Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology. 2009;77(3-4):244-253.
71. Borget I, Aupérin A, Pignon JP, et al.; Fédération Francophone de Cancérologie Digestive. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Oncology. 2006;71(1-2):40-48.
72. Franks PJ, Bosanquet N, Thorpe H, et al.; CLASICC trial participants. Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial). Br J Cancer. 2006;95(1):6-12.
73. Hopkins RB, Goeree R, Longo CJ. Estimating the national wage loss from cancer in Canada. Curr Oncol. 2010;17(2):40-49.
74. YabroffKR, Francisci S, Mariotto A, Mezzetti M, Gigli A, Lipscomb J. Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. J Natl Cancer Inst Monogr. 2013;46(1):1-6.
75. Gigli A, Warren JL, YabroffKR, et al. Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. J Natl Cancer Inst Monogr. 2013; 46(1):88-98.
76. Bradley CJ, Lansdorp-Vogelaar I, YabroffKR, et al. Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med. 2011;41(2):e5-e14.
77. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101(20):1412-1422.
78. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
79. Russell LB. Completing costs: patients' time. Med Care. 2009;47(7 Suppl 1):S89-S93.
80. Syse A, Tretli S, Kravdal O. The impact of cancer on spouses' labor earnings: a population-based study. Cancer. 2009;115(18 Suppl):4350-4361.
81. Sjövall K, Attner B, Lithman T, et al. Sick leave of spouses to cancer patients before and after diagnosis. Acta Oncol. 2010;49(4):467-473.
82. YabroffKR, Dowling E, Rodriguez J, et al. The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv. 2012;6(4):407-419.
83. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-1202.
84. Bradley CJ, Given CW, Luo Z, Roberts C, Copeland G, Virnig BA. Medicaid, Medicare, and the Michigan Tumor Registry: a linkage strategy. Med Decis Making. 2007;27(4):352-363.
85. Lipscomb J, Gillespie TW. State-level cancer quality assessment and research: building and sustaining the data infrastructure. Cancer J. 2011;17(4): 246-256.
86. Schrag D, Virnig BA, Warren JL. Linking tumor registry and Medicaid claims to evaluate cancer care delivery. Health Care Financ Rev. 2009;30(4): 61-73.
87. O'Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care. 1997;3(Suppl):S33-S39.
88. Manca A, Willan AR. 'Lost in translation': accounting for betweencountry differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics. 2006;24(11):1101-1119.
89. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating countryspecific cost-effectiveness from multinational clinical trials. Health Econ. 1998;7(6):481-493.
90. Gatta G, Trama A, Capocaccia R. Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. J Natl Cancer Inst Monogr. 2013;46(1):79-87.
91. Fishman PA, Hornbrook MC, Ritzwoller DP, O'Keeffe-Rosetti MC, Lafata JE, Salloum RG. The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented US health-care system. J Natl Cancer Inst Monogr. 2013; 46(1):99-105.
92. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82-88.
93. Fryback DG, Craig BM. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr. 2004;33:134-141.
94. Lipscomb J, YabroffKR, Hornbrook MC, et al. Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr. 2013; 46(1):124-130.